Background Previous reports showed that outcome of rabbit antithymocyte globulin (rATG) was not satisfactory as the first-line therapy for severe aplastic anemia (SAA). We explored a modifying schedule of administration of rATG. Design and Methods Outcomes of a cohort of 175 SAA patients, including 51 patients administered with standard protocol (3.55 mg/kg/d for 5 days) and 124 cases with optimized protocol (1.97 mg/kg/d for 9 days) of rATG plus cyclosporine (CSA), were analyzed retrospectively. Results Of all 175 patients, response rates at 3 and 6 months were 36.6% and 56.0%, respectively. 51 cases received standard protocol had poor responses at 3 (25.5%) and 6 months (41.2%). However, 124 patients received optimized protocol had better responses at 3 (41.1%, P = 0.14) and 6 (62.1%, P = 0.01). Higher incidences of infection (57.1% versus 37.9%, P = 0.02) and early mortality (17.9% versus 0.8%, P<0.001) occurred in patients received standard protocol compared with optimized protocol. The 5-year overall survival in favor of the optimized over standard rATG protocol (76.0% versus. 50.3%, P<0.001) was observed. By multivariate analysis, optimized protocol (RR = 2.21, P = 0.04), response at 3 months (RR = 10.31, P = 0.03) and shorter interval (<23 days) between diagnosis and initial dose of rATG (RR = 5.35, P = 0.002) were independent favorable predictors of overall survival. Conclusions Optimized instead of standard rATG protocol in combination with CSA remained efficacious as a first-line immunosuppressive regimen for SAA.
References
[1]
Thomas ED, Phillips JH, Finch CA (1964) Recovery from marrow failure following isogenic marrow infusion. JAMA 188: 1041–1043.
[2]
Pillow RP, Epstein RB, Buckner CD, Giblett ER, Thomas ED (1966) Treatment of bone-marrow failure by isogeneic marrow infusion. N Engl J Med 275: 94–97.
[3]
Thomas ED, Storb R, Fefer A, Slichter SJ, Bryant JI, et al. (1972) Aplastic anemia treated by marrow transplantation. Lancet 1: 284–289.
[4]
Speck B, Gluckman E, Haak HL, van Rood JJ (1977) Treatment of aplastic anemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions. Lancet 2: 1145–1148.
[5]
Gluckman E, Devergie A, Poros A, Degoulet P (1982) Results of immunosuppression in 170 cases of severe aplastic anemia. Report of the European Group of Bone Marrow Transplant (EGBMT). Br J Haematol 51: 541–550.
[6]
Champlin R, Ho W, Gale RP (1983) Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 308: 113–118.
[7]
Young N, Griffith P, Brittain E, Elfenbein G, Gardner F, et al. (1988) A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. Blood 72: 1861–1869.
[8]
de Planque MM, Bacigalupo A, Würsch A, Hows JM, Devergie A, et al. (1989) Long-term follow-up of severe aplastic anemia patients treated with antithymocyte globulin. Severe Aplastic Anemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol 73: 121–126.
[9]
Frickhofen N, Kaltwasser JP, Schrezenmeier H, Raghavachar A, Vogt HG, et al. (1991) Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med 324: 1297–1304.
[10]
Rosenfeld SJ, Kimball J, Vining D, Young NS (1995) Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 85: 3058–3065.
[11]
Passweg JR, Tichelli A (2009) Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling? Haematologica 94: 310–312.
[12]
Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, et al. (2011) Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 17: 291–299.
[13]
Risitano AM (2011) Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going. Br J Haematol 152: 127–140.
[14]
Risitano AM (2012) Immunosuppressive therapies in the management of acquired immune-mediated marrow failures. Curr Opin Hematol 19: 3–13.
[15]
Rosenfeld S, Follmann D, Nunez O, Young NS (2003) Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 289: 1130–1135.
[16]
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, et al. (2000) Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood 95: 1931–1934.
[17]
Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, et al. (2007) Severe Aplastic Anemia Working Party of the European Blood and Marrow Transplant Group. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 92: 11–18.
[18]
Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, et al. (2011) A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. Blood 117: 4434–4441.
[19]
Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, et al. (2007) Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 110: 1756–1761.
[20]
Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, et al. (1999) Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol 107: 330–334.
[21]
Scheinberg P, Nunez O, Young NS (2006) Retreatment with rabbit anti-thymocyte globulin and cyclosporine for patients with relapsed or refractory severe aplastic anemia. Br J Haematol 133: 622–627.
[22]
Atta EH, Dias DS, Marra VL, de Azevedo AM (2010) Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol 89: 851–859.
[23]
Afable MG, Shaik M, Sugimoto Y, Elson P, Clemente M, et al. (2011) Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 96: 1269–1275.
[24]
Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, et al. (2011) Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 365: 430–438.
[25]
Zheng Y, Liu Y, Chu Y (2006) Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol 34: 826–831.
[26]
Bacigalupo A, Hows J, Gluckman E, Nissen C, Marsh J, et al. (1988) Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anemia (SAA): a report of the EBMT SAA working party. Br J Haematol 70: 177–182.
[27]
Préville X, Flacher M, LeMauff B, Beauchard S, Davelu P, et al. (2001) Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 71: 460–468.
[28]
Agha IA, Rueda J, Alvarez A, Singer GG, Miller BW, et al. (2002) Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 73: 473–475.
[29]
Remberger M, Svahn BM, Mattsson J, Ringdén O (2004) Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation 78: 122–127.
[30]
Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, et al. (2012) Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood 119: 5391–5396.
[31]
Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, et al. (1999) A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 67: 1011–1018.
[32]
Gaber AO, First MR, Tesi RJ, Gaston RS, Mendez R, et al. (1998) Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 66: 29–37.
[33]
Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, et al. (2008) Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol 140: 197–205.
